Abstract
Introduction: Myastenia gravis is an autoimmune disease presenting throughout life. It is characterized by the presence of muscular weakness and easy tiring, secondary to a synaptic transmission alteration caused by the blockade and destruction of the acetylcholine receptors in the neuromuscular junction. The damage is caused by the presence of antiacetylcholine receptor antibodies, that confirm the diagnosis. It´s treatment is controversial, and as it is less frequent in children there is less experience of the disease characteristics as compared to in adults.
Objective: To actualized knowledge in paediatric miastenia gravis.
Method: MG publications in Cochrane, Medline and Doyma data base for the last ten years were reviewed.
Results: recent findings on the molecular pathophysiology, diagnosis and treatment are discussed
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2020 Revista Chilena de Pediatría